放射性药物治疗诊断市场基于(主要区域、市场参与者、规模和份额)- 预测至 2028 年

  • Report Code : TIPRE00024328
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 185
Buy Now

Radiopharmaceutical Theranostics Market Size Report – Share and Growth 2028

Buy Now

 

放射性药物治疗诊断市场规模预计将从 2022 年的 18.1458 亿美元增长到 2028 年的 34.4197 亿美元;预计 2022 年至 2028 年的复合年增长率为 11.3%。

放射性药物治疗诊断市场根据产品类型、放射性同位素、来源、应用、适应症、最终用户和地理位置进行细分。该报告提供了对市场的深入分析和见解,强调了放射性药物治疗诊断市场中存在的动态、趋势和机会等参数。它还提供了全球放射性药物治疗诊断市场主要市场参与者的竞争格局分析。

 

市场洞察

 

心血管疾病治疗应用的不断增长推动全球放射性药物治疗诊断市场的增长

心血管疾病是21世纪最常见的慢性疾病之一,死亡率很高。由于久坐的生活方式,心血管疾病是发达国家死亡和发病的主要原因。此外,肥胖和糖尿病以及相关疾病与心血管疾病有关,并正在成为共病。此外,冠状动脉阻塞等并发症是成年人死亡的首要原因之一,导致动脉壁内膜(主要在颈动脉)形成血栓斑块。根据美国国家生物技术中心的数据,2015年全球约有1770万人死于心血管疾病。在这方面,据估计,到 2030 年,心血管疾病造成的死亡人数可能增加到 2200 万。心血管疾病的治疗应用包括纳米药物 在心绞痛、心肌炎、心肌梗死、心包疾病、血栓形成、动脉粥样硬化、高脂血症、高血压、肺动脉高压和中风中的应用。治疗诊断纳米药物可以延长体循环,逃避宿主防御系统,并将治疗诊断剂递送到目标部位,在细胞和分子水平上进行成像和治疗。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

放射性药物治疗诊断市场:

放射性药物治疗诊断市场

  • 复合年增长率(2022 - 2028)
    11.3%
  • 2022 年市场规模
    18.1 亿美元
  • 2028 年市场规模
    34.4 亿美元

市场动态

增长动力
  • 財政部
  • 財政部
  • 財政部
未来的趋势
  • 財政部
  • 財政部
  • 財政部
机会
  • 財政部
  • 財政部
  • 財政部

关键人物;主力;重要一员

  •  
  • 拜耳公司
  • 通用电气医疗科技公司
  • Lantheus 医学成像公司
  • Telix 制药有限公司
  • 康德乐公司
  • 先进加速器应用公司
  • 欢庆放射药物公司
  • 诊疗学

区域概况

  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

产品类别
  • 阿尔法辐射源
  • β 辐射源
  • 正电子发射断层扫描
来源
  • 核反应堆和回旋加速器
应用
  • 靶向治疗
最终用户
  • 医院
  • 诊断影像中心
  • 学术及研究机构
  • 其他的
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

根据美国疾病控制与预防中心 (CDC) 2022 年的报告,心脏病是美国男性和女性死亡的主要原因。2020 年,心脏病导致美国约 697,000 人死亡,即每 5 人中就有 1 人死亡。美国国立卫生研究院 (NIH) 的一份报告指出,治疗诊断纳米粒子在医学领域引起了广泛关注,因为该技术有助于克服与​​心血管疾病相关的复杂性和病理生理并发症。动脉粥样硬化患者的心血管成像提供了有助于治疗心血管疾病的病理生理学证据。此外,治疗诊断纳米粒子可以与多种成像技术相结合,例如磁共振成像 (MRI)、正电子发射断层扫描 (PET) 和计算机断层扫描 (CT)。迄今为止,临床实验室已经开展了各种临床研究。构建了三合一治疗复合物,将聚合物光声探针与纳米粒子 PLCDP@PMH 相结合。临床体内评估表明,PLCDP@PMH 为患者早期动脉粥样硬化检测的诊疗方法提供了有利的优势。

 

基于产品类型的洞察

根据产品类型,放射性药物治疗诊断市场分为正电子发射断层扫描 (PET) 示踪剂、β 发射体和 α 发射体。2022 年,正电子发射断层扫描 (PET) 示踪剂细分市场占据全球放射性药物治疗诊断市场的最大份额,预计在预测期内将实现最高复合年增长率。

 

放射性药物治疗诊断市场(按产品类型)——2022 年至 2028 年

 

 

  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

基于放射性同位素的见解

 

根据放射性同位素,放射性药物治疗诊断市场分为镥 (Lu) 177、镓-68、碘-131、碘-123、锝-99、钇-90 (Y-90)、铜 (Cu) 64、18F、铜 (Cu) 67 等。2022 年,镥 (Lu) 177 部分占据全球放射性药物治疗诊断市场的最大市场份额,预计在预测期内将实现最高复合年增长率。

 

基于来源的洞察

根据来源,放射性药物治疗诊断市场分为回旋加速器和核反应堆。回旋加速器部分在 2022 年占据了更大的市场份额,预计在预测期内将录得更高的复合年增长率。

 

基于应用的洞察

根据应用,放射性药物治疗诊断市场分为靶向治疗 (Rx) 和伴随诊断 (CDx)。2022 年,靶向治疗 (Rx) 领域占据了更大的市场份额,预计在预测期内将实现更高的复合年增长率。

 

基于指示的见解

根据适应症,放射性药物治疗诊断市场分为肿瘤科、神经科、心脏病科等。肿瘤科在 2022 年占据了最大的市场份额,预计在预测期内将实现最高的复合年增长率。

 

基于最终用户的洞察

根据最终用户,放射性药物治疗诊断市场细分为医院、诊断成像中心、学术和研究机构等。医院部门在 2022 年占据了最大的市场份额。然而,预计学术和研究机构部门在预测期内的复合年增长率最高。医院采用技术先进的系统来治疗心脏动脉瘤、神经系统动脉瘤、肿瘤肿瘤和其他类似疾病。各种疾病患病率的上升和医院数量的增加促进了医院部门市场的增长。

放射性药物治疗诊断市场参与者采用有机策略,例如产品发布和扩展,以扩大其足迹和产品组合并满足不断增长的需求。市场上见证的无机增长战略是合作伙伴关系和协作。这些增长战略使市场参与者能够扩大业务并增强其地理影响力。此外,收购、合作伙伴关系和其他增长战略有助于他们加强客户群。

  • 2022 年 10 月,Telix 的 Illuccix 获得加拿大卫生部批准,这是一种用于制备镓 (68Ga) 戈泽托肽注射液的试剂盒。该产品可用于中高风险前列腺癌的分期和重新分期以及复发性前列腺癌的肿瘤组织定位。Illuccix 是首个获得加拿大监管部门批准的 PSMA PET 成像剂。加拿大卫生部是全球第三个批准 Illuccix 的监管机构,该产品在澳大利亚和美国有售。
  • 2021 年 12 月,GE Healthcare 与 Minerva Imaging 达成战略合作伙伴关系,以加速靶向放射性核素疗法(治疗诊断学)的商业化推出。放射性核素疗法是一种精准医疗,通过血液输送放射性物质以靶向癌细胞并对其进行特异性照射。与传统癌症疗法相比,这有助于减少潜在的副作用。

 

公司简介 - 放射性药物治疗诊断市场

  • 拜耳公司
  • 通用电气医疗科技公司
  • Lantheus 医学成像公司
  • Telix 制药有限公司
  • 康德乐公司
  • 先进加速器应用公司
  • 欢庆放射药物公司
  • 诊疗学
  • NuView 生命科学

放射性药物治疗诊断市场报告范围

报告属性细节
2022 年市场规模18.1亿美元
2028 年市场规模34.4 亿美元
全球复合年增长率(2022 - 2028)11.3%
历史数据2020-2021
预测期2023-2028
涵盖的领域按产品类型
  • 阿尔法辐射源
  • β 辐射源
  • 正电子发射断层扫描
按来源
  • 核反应堆和回旋加速器
按应用
  • 靶向治疗
按最终用户
  • 医院
  • 诊断影像中心
  • 学术及研究机构
  • 其他的
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  •  
  • 拜耳公司
  • 通用电气医疗科技公司
  • Lantheus 医学成像公司
  • Telix 制药有限公司
  • 康德乐公司
  • 先进加速器应用公司
  • 欢庆放射药物公司
  • 诊疗学
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which application held the largest share in the radiopharmaceutical theranostics market?

Answer: - The targeted therapeutic [Rx] segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 63.28% in 2022.

Which indication held the largest share in the radiopharmaceutical theranostics market?

The oncology segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 62.18% in 2022.

Which end user held the largest share in the radiopharmaceutical theranostics market?

The hospitals segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 36.28% in 2022.

Who are the key players in the radiopharmaceutical theranostics market?

The radiopharmaceutical theranostics market majorly consists of the players such Bayer AG, GE HealthCare Technologies Inc, Curium, Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc, Advanced Accelerator Applications S.A.; Jubilant Radiopharma, Theragnostics, and NuView Life Sciences amongst others.

Which source held the largest share in the radiopharmaceutical theranostics market?

The cyclotrons segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 60.42% in 2022.

Which radioisotope held the largest share in the radiopharmaceutical theranostics market?

The Lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market and held the largest market share of 24.34% in 2022.

Which product type leads the radiopharmaceutical theranostics market?

The positron emission tomography (PET) tracers segment held the largest share of the market in the global radiopharmaceutical theranostics market and held the largest market share of 44.76% in 2022.

What is the market CAGR value of radiopharmaceutical theranostics market during forecast period?

The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 11.3%.

What are the driving factors for the radiopharmaceutical theranostics market across the globe?

Key factors that are driving the growth of this market are rising incidence of cancer and the growing application in the treatment of cardiovascular disorders are expected to boost the market growth for the radiopharmaceutical theranostics over the years.

What is radiopharmaceutical theranostics?

Radiopharmaceuticals are radioisotopes that are bound to biological molecules that target specific tissues, organs, or cells within the human body. Radioisotopes emitting gamma rays are useful for diagnostic imaging where the radiation escapes the body. Nuclear medicine imaging generally utilizes radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics’. In theranostics, radiopharmaceuticals are used for therapeutic and diagnostic purposes by targeting one specific tumor receptor.

The List of Companies - Radiopharmaceutical Theranostics Market

  1. Bayer AG
  2. GE HealthCare Technologies Inc
  3. Curium
  4. Lantheus Medical Imaging, Inc.     
  5. Telix Pharmaceuticals Ltd.
  6. Cardinal Health Inc
  7. Advanced Accelerator Applications S.A.
  8. Jubilant Radiopharma
  9. Theragnostics
  10. NuView Life Sciences

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports